# Study on Human Bioequivalence of Triprerelin Acetate for Injection

> **NCT06683066** · PHASE1 · RECRUITING · sponsor: **The Affiliated Hospital of Qingdao University** · enrollment: 120 (estimated)

## Conditions studied

- Prostate Cancer (CRPC)

## Interventions

- **DRUG:** Triprorelin for injection
- **DRUG:** Diphereline

## Key facts

- **NCT ID:** NCT06683066
- **Lead sponsor:** The Affiliated Hospital of Qingdao University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-04
- **Primary completion:** 2025-09-04
- **Final completion:** 2025-09-04
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2024-11-12

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06683066

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06683066, "Study on Human Bioequivalence of Triprerelin Acetate for Injection". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06683066. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*